China Junshi's potential Covid drug shows promise in small trial
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Sunday
July 03, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
SUNDAY, JULY 03, 2022
China Junshi's potential Covid drug shows promise in small trial

Coronavirus chronicle

Reuters
18 May, 2022, 03:35 pm
Last modified: 18 May, 2022, 03:40 pm

Related News

  • Chance of finding missing crew off Hong Kong 'very slim' after storm, authorities say
  • India records 16,103 new Covid cases, 31 deaths in 24 hours
  • Boeing disappointed after China's top three airlines buy 300 Airbus planes
  • China lashed by year's first typhoon, record rains forecast
  • 6 Covid deaths, 1,105 cases reported in 24 hours

China Junshi's potential Covid drug shows promise in small trial

Reuters
18 May, 2022, 03:35 pm
Last modified: 18 May, 2022, 03:40 pm
Representational image.
Representational image.

An antiviral oral drug being co-developed by Shanghai Junshi Biosciences' subsidiary and other Chinese institutes showed early promise in speeding the clearing of virus in Covid-19 patients, according to a small clinical trial.

The drug, called VV116, is a derivative of Gilead Sciences Inc's Covid drug remdesivir and was approved for use in moderate to severe cases in Uzbekistan last year.

The viral shedding period, defined by its trial researchers as the duration between the first positive Covid test result and the first negative one, was 8.56 days for participants who took the experimental treatment within five days from the first positive test result.

That was shorter than 11.13 days seen in the control group, peer-reviewed data showed.

The trial involved 136 mild or moderate adult Covid infections recruited in March in China. Participants were given either the five-day course oral drug along with standard treatment or standard treatment only, researchers said in a paper published in the journal Emerging Microbes & Infections.

Overall, there was no significant difference between the viral shedding period for those who took VV116 more than five days after first positive result and the control group.

Limitations of the study include the small trial size and a higher portion of participants in the control group reporting symptoms, which could result in potential bias that researchers had to adjust with statistic model, the paper said.

The drug is undergoing a Phase III trial to evaluate its efficacy in mild to moderate patients in comparison with Pfizer Inc's oral pill Paxlovid, and a separate Phase III trial in moderate to severe cases.

China has approved Paxlovid as well as Brii Biosciences Ltd's antibody-based injection for mild and moderate Covid patients with high risk of progressing to severe conditions.

China

Covid drug / Antiviral oral drug / Covid / Covid -19 / Oral Covid treatment / Shanghai Junshi Biosciences / china

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo of Bangladesh Secretariat/Collected
    Govt stops purchasing new cars for ministries, departments
  • Photo :Noor-A-Alam
    SSC exams to be held in August
  • No more honorarium for government meetings
    No more honorarium for government meetings

MOST VIEWED

  • A man helps his son to wear mask at Covid-19 test centre at KSRTC bus stand in Bengaluru.(PTI)
    India records 16,103 new Covid cases, 31 deaths in 24 hours
  • Former North Korean defectors living in South Korea, release balloons containing one dollar banknotes, radios, CDs and leaflets denouncing the North Korean regime, towards the north near the demilitarized zone which separates the two Koreas in Paju, north of Seoul January 15, 2014. REUTERS/Kim Hong-Ji/File Photo
    North Korea blames 'alien things' near border with South for Covid outbreak
  • People wearing protective face masks commute amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea March 30, 2020, in this photo released by Kyodo. Picture taken March 30, 2020. Mandatory credit Kyodo/via REUTERS
    S Korea says leaflets sent by defectors unlikely to be cause of Covid in N Korea
  • Test tubes are seen in front of displayed Pfizer and Biontech logos in this illustration taken, May 21, 2021. Reuters: llustration
    BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    S Korea approves first domestically developed Covid vaccine
  • Photo: Collected
    US medical experts call for Omicron-specific Covid boosters

Related News

  • Chance of finding missing crew off Hong Kong 'very slim' after storm, authorities say
  • India records 16,103 new Covid cases, 31 deaths in 24 hours
  • Boeing disappointed after China's top three airlines buy 300 Airbus planes
  • China lashed by year's first typhoon, record rains forecast
  • 6 Covid deaths, 1,105 cases reported in 24 hours

Features

A Glittery Eid

A Glittery Eid

4h | Mode
Rise’s target customers are people who crave to express themselves through what they wear, and their clothing line is not relegated to any age range.

Level up your Eid game with Rise

4h | Mode
Stefan Dercon, a Professor of Economics at the University of Oxford and former Chief Economist of the Department of International Development (DFID). Illustration: TBS

Renewing the ‘elite bargain’ for Bangladesh’s future growth

7h | Panorama
The eye-catching commuter: Suzuki Gixxer SF 155

The eye-catching commuter: Suzuki Gixxer SF 155

1d | Wheels

More Videos from TBS

Chirkutt performs on Fete de La Music Fest

Chirkutt performs on Fete de La Music Fest

6h | Videos
Madhuri Sanchita's seed ornaments exhibition

Madhuri Sanchita's seed ornaments exhibition

6h | Videos
Bangabandhu Tunnel to change lives of million

Bangabandhu Tunnel to change lives of million

17h | Videos
Sowari Ghat's fresh fish market

Sowari Ghat's fresh fish market

18h | Videos

Most Read

1
Padma Bridge from satellite. Photo: Screengrab
Bangladesh

Padma Bridge from satellite 

2
Meet the man behind 'Azke amar mon balo nei'
Splash

Meet the man behind 'Azke amar mon balo nei'

3
TBS Illustration
Education

Universities may launch online classes again after Eid

4
Photo: TBS
Bangladesh

Motorcycles banned on Padma Bridge 

5
Photo: Collected
Economy

Tech startup ShopUp bags $65m in Series B4 funding

6
World Bank to give Bangladesh $18b IDA loans in next five years
Economy

World Bank to give Bangladesh $18b IDA loans in next five years

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab
BENEATH THE SURFACE
Launch operators on various river routes see a steep drop in passengers after the opening of the the Padma Bridge. Photo: TBS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net